We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 5.79 | 5.50 | 6.08 | - | 170,332 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.66 | 11.66M |
Date | Subject | Author | Discuss |
---|---|---|---|
17/11/2020 08:57 | You’re down over 50% because you went all in and now you want to blame the CEO. What a pathetic rat. He’s done more to help the world this year than you will in your entire life. Filtered once and for all. | 74tom | |
17/11/2020 08:54 | "I would probably wait to see an update" I'd LOVE to see an update - but we don't get one, do we? Not about MAP Not about recruitment / start of P3 Not about discussions with Big Pharma Occam's Razor suggests that the reason they're saying nothing is because they have nothing to say... | sloppyjoe2 | |
17/11/2020 08:38 | I would probably wait to see an update before judging how well they are managing things..but can assure the kinds of developments shareholders want are not done overnight on a whim. | kooba | |
17/11/2020 08:37 | "It's our time" has a hollow ring to it now don't you think ? | paradise city | |
17/11/2020 08:34 | Anyone who bought SNG after Manic Monday is now showing significant paper losses of up to 50%. I think that useless incompetent Marsden owes shareholders a FULL update - what's happening with MAP, and whether a single patient *anywhere* in Europe is being treated under it; what talks are ongoing with pharma partners; and why to date there has not been a SINGLE EUA *anywhere*... | sloppyjoe2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions